Pipeline Of CD47 And SIRP-Alpha Targeted Immunotherapy Report Now Available. See Which Of 20+ Clinical-Stage Molecules Solved The Anemia Problem That's Sidelined Rival Programs
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" has been added to ResearchAndMarkets.com's offering.
The CD47 and SIRP-alpha Targeted Immunotherapy Competitive Intelligence Report provides an up-to-date assessment of companies, therapeutic candidates and research programs focused on the CD47-SIRP? signaling pathway. Prepared on demand within one working day of order placement, the report supports competitive benchmarking, business development, licensing evaluations and strategic decision-making across the rapidly evolving immuno-oncology market.
The report identifies active CD47 and SIRP? targeted research and development programs by development phase and presents the findings in a structured tabular format. It also provides concise profiles of therapeutic candidates, including their mechanisms, clinical status and drug modalities. Technologies covered include monoclonal antibodies, bispecific and multispecific antibodies, fusion proteins, other protein biologics, RNA and mRNA therapies, and small-molecule inhibitors.
Macrophage-mediated phagocytosis is controlled by a balance of activating and inhibitory signaling pathways. CD47 suppresses phagocytosis through its interaction with signal regulatory protein alpha, or SIRP?, expressed on macrophages and other myeloid cells. Malignant cells can exploit this pathway to evade immune-mediated clearance. Elevated CD47 expression has been documented across multiple hematological malignancies and solid tumors, with increased expression frequently associated with aggressive disease and unfavorable clinical outcomes.
Preclinical research has demonstrated that disruption of CD47-SIRP? signaling can restore macrophage activity and generate antitumor responses in vitro and in vivo. Early clinical findings have further supported the therapeutic potential of targeting this pathway, encouraging investment in differentiated antibodies, fusion proteins and next-generation combination approaches.
A major area of innovation involves dual-function molecules engineered to neutralize CD47-mediated immunosuppression while promoting Fc receptor-dependent macrophage activity. The properties of the Fc region can materially influence efficacy, tolerability and pharmacology. As a result, IgG1, IgG4 and Fc-inactivated formats may produce distinct biological and clinical profiles. The report examines these design differences as important factors in competitor evaluation and product differentiation.
Safety remains a central challenge in CD47 drug development. Because CD47 is present on red blood cells, systemic CD47 binding may cause hematologic adverse effects, including severe anemia. Red blood cell engagement can also reduce circulating drug exposure through target-mediated clearance and may interfere with laboratory blood typing procedures.
Accordingly, reduced or absent binding to human red blood cells has become a significant competitive attribute among CD47-targeted therapies. Developers are pursuing selective epitopes, optimized dosing strategies, localized activity, bispecific targeting and alternative SIRP?-directed approaches to improve the therapeutic index while preserving antitumor activity.
The global CD47-SIRP? immunotherapy pipeline includes directly acting monospecific, bispecific and multispecific inhibitors across preclinical and clinical development. More than 20 distinct candidates targeting this pathway have entered clinical development, reflecting sustained interest in macrophage checkpoint inhibition as a cancer treatment strategy.
By consolidating pipeline status, drug modality, molecular design, clinical progress and differentiation factors, the CD47 and SIRP-alpha Targeted Immunotherapy Competitive Intelligence Report delivers a focused view of the current competitive landscape. It enables stakeholders to monitor emerging therapies, assess development risks, identify partnership opportunities and compare the strategic positioning of leading CD47 and SIRP? immunotherapy programs.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment